Literature DB >> 31740559

Activity of Imipenem-Relebactam against a Large Collection of Pseudomonas aeruginosa Clinical Isolates and Isogenic β-Lactam-Resistant Mutants.

Pablo A Fraile-Ribot1, Laura Zamorano2, Rocío Orellana1, Ester Del Barrio-Tofiño1, Irina Sánchez-Diener1, Sara Cortes-Lara1, Carla López-Causapé1, Gabriel Cabot1, Germán Bou3, Luis Martínez-Martínez4, Antonio Oliver2.   

Abstract

Imipenem and imipenem-relebactam MICs were determined for 1,445 Pseudomonas aeruginosa clinical isolates and a large panel of isogenic mutants showing the most relevant mutation-driven β-lactam resistance mechanisms. Imipenem-relebactam showed the highest susceptibility rate (97.3%), followed by colistin and ceftolozane-tazobactam (both 94.6%). Imipenem-relebactam MICs remained ≤2 μg/ml in all 16 isogenic PAO1 mutants and in 8 pairs of extensively drug-resistant clinical strains that had developed resistance to ceftolozane-tazobactam and ceftazidime-avibactam due to mutations in OXA-10 or AmpC.
Copyright © 2020 American Society for Microbiology.

Entities:  

Keywords:  Pseudomonas aeruginosazzm321990; antibiotic resistance; extensively drug resistant; imipenem-relebactam; multidrug resistance; whole-genome sequencing; β-lactam resistance mechanisms

Mesh：

Substances：

Year:  2020        PMID： 31740559      PMCID： PMC6985745          DOI： 10.1128/AAC.02165-19

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  16 in total

1.  Activity of imipenem-relebactam against multidrug-resistant Pseudomonas aeruginosa from the United States - SMART 2015-2017.

Authors:  James A Karlowsky; Sibylle H Lob; Katherine Young; Mary R Motyl; Daniel F Sahm
Journal:  Diagn Microbiol Infect Dis       Date:  2019-05-08       Impact factor: 2.803

2.  Mechanisms leading to in vivo ceftolozane/tazobactam resistance development during the treatment of infections caused by MDR Pseudomonas aeruginosa.

Authors:  Pablo A Fraile-Ribot; Gabriel Cabot; Xavier Mulet; Leonor Periañez; M Luisa Martín-Pena; Carlos Juan; José L Pérez; Antonio Oliver
Journal:  J Antimicrob Chemother       Date:  2018-03-01       Impact factor: 5.790

3.  Activity of imipenem/relebactam against MDR Pseudomonas aeruginosa in Europe: SMART 2015-17.

Authors:  Sibylle H Lob; James A Karlowsky; Katherine Young; Mary R Motyl; Stephen Hawser; Nimmi D Kothari; Melinda E Gueny; Daniel F Sahm
Journal:  J Antimicrob Chemother       Date:  2019-08-01       Impact factor: 5.790

Review 4.  Host and Pathogen Biomarkers for Severe Pseudomonas aeruginosa Infections.

Authors:  Carlos Juan; Carmen Peña; Antonio Oliver
Journal:  J Infect Dis       Date:  2017-02-15       Impact factor: 5.226

5.  Spanish nationwide survey on Pseudomonas aeruginosa antimicrobial resistance mechanisms and epidemiology.

Authors:  Ester Del Barrio-Tofiño; Laura Zamorano; Sara Cortes-Lara; Carla López-Causapé; Irina Sánchez-Diener; Gabriel Cabot; Germán Bou; Luis Martínez-Martínez; Antonio Oliver
Journal:  J Antimicrob Chemother       Date:  2019-07-01       Impact factor: 5.790

6.  Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients.

Authors:  Bartolome Moya; Laura Zamorano; Carlos Juan; José L Pérez; Yigong Ge; Antonio Oliver
Journal:  Antimicrob Agents Chemother       Date:  2010-01-19       Impact factor: 5.191

Review 7.  Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Second-generation β-Lactam/β-Lactamase Inhibitor Combinations.

Authors:  David van Duin; Robert A Bonomo
Journal:  Clin Infect Dis       Date:  2016-04-20       Impact factor: 9.079

8.  Activity of MK-7655 combined with imipenem against Enterobacteriaceae and Pseudomonas aeruginosa.

Authors:  David M Livermore; Marina Warner; Shazad Mushtaq
Journal:  J Antimicrob Chemother       Date:  2013-05-21       Impact factor: 5.790

9.  Ceftolozane-Tazobactam for the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Infections: Clinical Effectiveness and Evolution of Resistance.

Authors:  Ghady Haidar; Nathan J Philips; Ryan K Shields; Daniel Snyder; Shaoji Cheng; Brian A Potoski; Yohei Doi; Binghua Hao; Ellen G Press; Vaughn S Cooper; Cornelius J Clancy; M Hong Nguyen
Journal:  Clin Infect Dis       Date:  2017-07-01       Impact factor: 9.079

10.  RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections.

Authors:  Johann Motsch; Cláudia Murta de Oliveira; Viktor Stus; Iftihar Köksal; Olexiy Lyulko; Helen W Boucher; Keith S Kaye; Thomas M File; Michelle L Brown; Ireen Khan; Jiejun Du; Hee-Koung Joeng; Robert W Tipping; Angela Aggrey; Katherine Young; Nicholas A Kartsonis; Joan R Butterton; Amanda Paschke
Journal:  Clin Infect Dis       Date:  2020-04-15       Impact factor: 9.079
View more
  19 in total

Review 1.  Resistance to Novel β-Lactam-β-Lactamase Inhibitor Combinations: The "Price of Progress".

Authors:  Krisztina M Papp-Wallace; Andrew R Mack; Magdalena A Taracila; Robert A Bonomo
Journal:  Infect Dis Clin North Am       Date:  2020-09-30       Impact factor: 5.982

Review 2.  New β-Lactam-β-Lactamase Inhibitor Combinations.

Authors:  Dafna Yahav; Christian G Giske; Alise Grāmatniece; Henrietta Abodakpi; Vincent H Tam; Leonard Leibovici
Journal:  Clin Microbiol Rev       Date:  2020-11-11       Impact factor: 26.132

Review 3.  The Ins and Outs of Susceptibility Testing for New β-Lactam/β-Lactamase Inhibitor Combinations for Gram-Negative Organisms.

Authors:  Tanis C Dingle; Johann Pitout
Journal:  J Clin Microbiol       Date:  2022-04-07       Impact factor: 11.677

4.  Imipenem/Relebactam Resistance in Clinical Isolates of Extensively Drug Resistant Pseudomonas aeruginosa: Inhibitor-Resistant β-Lactamases and Their Increasing Importance.

Authors:  Andrea M Hujer; Christopher R Bethel; Magdalena A Taracila; Steven H Marshall; Laura J Rojas; Marisa L Winkler; Ronald E Painter; T Nicholas Domitrovic; Richard R Watkins; Ayman M Abdelhamed; Roshan D'Souza; Andrew R Mack; Richard C White; Thomas Clarke; Derrick E Fouts; Michael R Jacobs; Katherine Young; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2022-04-18       Impact factor: 5.938

5.  In Vitro Activity of Ceftolozane-Tazobactam, Imipenem-Relebactam, Ceftazidime-Avibactam, and Comparators against Pseudomonas aeruginosa Isolates Collected in United States Hospitals According to Results from the SMART Surveillance Program, 2018 to 2020.

Authors:  James A Karlowsky; Sibylle H Lob; C Andrew DeRyke; David W Hilbert; Michael T Wong; Katherine Young; Fakhar Siddiqui; Mary R Motyl; Daniel F Sahm
Journal:  Antimicrob Agents Chemother       Date:  2022-05-02       Impact factor: 5.938

Review 6.  Class C β-Lactamases: Molecular Characteristics.

Authors:  Alain Philippon; Guillaume Arlet; Roger Labia; Bogdan I Iorga
Journal:  Clin Microbiol Rev       Date:  2022-04-18       Impact factor: 50.129

7.  In Vitro Susceptibility of Multidrug-Resistant Pseudomonas aeruginosa following Treatment-Emergent Resistance to Ceftolozane-Tazobactam.

Authors:  Abigail M Rubio; Ellen G Kline; Chelsea E Jones; Liang Chen; Barry N Kreiswirth; M Hong Nguyen; Cornelius J Clancy; Vaughn S Cooper; Ghady Haidar; Daria Van Tyne; Ryan K Shields
Journal:  Antimicrob Agents Chemother       Date:  2021-05-18       Impact factor: 5.191

8.  Emergence of Resistance to Novel Cephalosporin-β-Lactamase Inhibitor Combinations through the Modification of the Pseudomonas aeruginosa MexCD-OprJ Efflux Pump.

Authors:  María A Gomis-Font; Cristina Pitart; Ester Del Barrio-Tofiño; Yuliya Zboromyrska; Sara Cortes-Lara; Xavier Mulet; Francesc Marco; Jordi Vila; Carla López-Causapé; Antonio Oliver
Journal:  Antimicrob Agents Chemother       Date:  2021-07-16       Impact factor: 5.191

9.  Ceftolozane/Tazobactam and Imipenem/Relebactam Cross-Susceptibility Among Clinical Isolates of Pseudomonas aeruginosa From Patients With Respiratory Tract Infections in ICU and Non-ICU Wards-SMART United States 2017-2019.

Authors:  Sibylle H Lob; Daryl D DePestel; C Andrew DeRyke; Krystyna M Kazmierczak; Katherine Young; Mary R Motyl; Daniel F Sahm
Journal:  Open Forum Infect Dis       Date:  2021-06-16       Impact factor: 3.835

10.  Cefiderocol Activity Against Clinical Pseudomonas aeruginosa Isolates Exhibiting Ceftolozane-Tazobactam Resistance.

Authors:  Patricia J Simner; Stephan Beisken; Yehudit Bergman; Andreas E Posch; Sara E Cosgrove; Pranita D Tamma
Journal:  Open Forum Infect Dis       Date:  2021-06-12       Impact factor: 3.835
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.